Kenvue stock

KVUE · NYSE · USD

Compare Kenvue
$19.31Change from previous close: −1.28%Absolute change: −$0.25

Close · October 30, 2026

Price history

+35.60% over the period

1 year: from $14.24 (October 30, 2025) to $19.31 (October 30, 2026), +35.60%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
October 30, 2026$19.31
September 30, 2026$17.66
August 31, 2026$18.88
July 31, 2026$19.24
June 30, 2026$19.11
May 29, 2026$17.28
April 30, 2026$17.53
March 31, 2026$17.24
February 27, 2026$19.12
January 30, 2026$17.40
December 31, 2025$17.25
November 28, 2025$17.35
October 31, 2025$14.37
October 30, 2025$14.24

At a glance

  • The company

    Consumer health company offering over-the-counter medicines, self-care products, skin and beauty care, and essential health products across multiple brands

  • Latest results

    Quarter to September 30, 2026 · EPS $0.22 (estimate $0.37)

TickerLandia's take on Kenvue

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$15.94
52-wk high$20.13

−4.07% from the 52-week high

Analysts · 12 analysts

Average target$19.50+0.98% vs. price

Buy 2 · Hold 10 · Sell 0 · Hold

TickerLandia Fingerprint: Kenvue

Compared with similar companies: very low risk.

Financials and price compared with 27 companies in the household & personal products industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Kenvue is cheaper than similar companies

Kenvue's P/E (trailing 12 months): 21.9, −16% against the median of a group of 11 similar companies (26.0).

Compared with 11 similar companies

Kenvue's metrics compared with similar companies
MetricKenvuePosition in the groupBand
P/E (trailing 12 months)21.9Middle
Forward P/E15.6Low
Operating margin19.2%Middle
ROE16.3%Middle
Debt/equity0.82Middle

Grey band: the middle half of the group; tick: the median; dot: Kenvue. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$3.89B

Latest quarter · Q3 2026

Net income

$430M

Latest quarter · Q3 2026

Quarterly net margin

11.1%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$37.11B
P/E
21.9
EPS
$0.88
Volume
66.38M
Daily trading
€354.96M
Dividend yield
4.32%
Last ex-dividend on September 21, 2026

How Kenvue is changing

All results
  • Revenue grew 0.9% a year on average over the last 5 years

  • Profits turn into cash: free cash flow equal to 138% of net income

  • Shares outstanding up 12.1% in 3 years

Returns

Kenvue returns with dividends

$1,000 invested in Kenvue 3 years ago, on October 30, 2023, would be worth $1,186 today with dividends reinvested: +18.59% in total, +5.85% per year. On price alone it would be $1,036 (+3.59%).

PeriodKenvueS&P 500$1,000 becomes
1 month+9.34%−3.17%$1,093
6 months+10.15%+5.15%$1,102
Year to date+11.94%+8.34%$1,119
1 year+43.75%+11.11%$1,437
3 years+18.59%+81.91%$1,186

Over the last 6 months it has done better than 48% of the stocks in the Consumer sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Kenvue: technical analysis

Kenvue is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 29.8% below its all-time closing high ($27.50, May 15, 2023).

Trend
Upward
RSI (14 sessions)
60
Between 30 and 70
vs 200-session average
+6.15%

Support and resistance

Price areas where Kenvue has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$20.02+3.69%3 touches, last on October 22, 2026
  2. Last price$19.31
  3. Support$19.25−0.34%2 touches, last on August 14, 2026
  4. Support$18.67−3.31%4 touches, last on August 12, 2026
  5. Support$17.87−7.44%7 touches, last on June 22, 2026

Volatility and risk

Over the last year it has moved little with the S&P 500.

Beta (1 year) vs S&P 500
0.08
Volatility (60 sessions, annualised)
21.4%
Largest fall in the last year
−13.26%

Close of October 30, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

The company

Kenvue and its competitors

Consumers in the United States, the rest of North America, Europe, the Middle East, Africa, Asia-Pacific and Latin America are the markets served by Kenvue, a consumer health company. Its three segments are Self Care, Skin Health and Beauty, and Essential Health, covering over-the-counter medicines, skin and hair care, sun products, oral and baby care, women's health, wound care, tampons, cosmetics and vitamins. Brands in the portfolio include Tylenol, Neutrogena, Johnson's, Listerine, Zyrtec and BAND-AID.

Headquarters
Summit, United States
Employees
21,780
Founded
2022
Chief executive
Kirk Perry
Kenvue and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
KenvueKVUE$37.11B19.2%21.9+10.15%
Estée Lauder CompaniesEL$39.35B11.9%108.6+30.19%
Church And DwightCHD$27.08B18.6%35.2+19.60%
Kimberly-ClarkKMB$68.33B17.3%21.2+12.76%
Colgate-PalmoliveCL$79.18B20.7%38.8+13.03%
CloroxCLX$12.93B14.3%19.2+17.97%

Same industry or related industries, similar size. Compare Kenvue with its competitors · Full profile